Incidence of Expression of Tumor Antigens in Cancer Tissue From Patients With Pathologically Demonstrated Bladder Cancer

GlaxoSmithKline (GSK)

Status: Completed

Conditions: Neoplasms, Urinary Bladder

Treatments: Other: Data acquisition and analysis

Study type: Observational

Funder types: Industry

Identifiers

NCT01706185

111294

Details and patient eligibility

About

This study aims to analyze the incidence of expression of MAGE-A3, MAGE-C2, NY-ESO-1, LAGE-1, WT1 and PRAME tumor antigens in cancer tissue from patients with pathologically demonstrated bladder cancer.

Full description

There will be no procedure(s) or treatment(s) carried out on patients. All data and samples will be taken from those already stored at the investigation sites. Clinical data collected will include patient demographics (age, gender), Tumor, Node, Metastasis (staging system) [TNM stage], and histopathologic description only. Strict anonymity of patient data will be maintained.

This retrospective study is based upon the analysis of archived formalin-fixed paraffin-embedded tissue samples and patient-related data already available at the investigational site.

Enrollment: 156 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

For inclusion of a tissue sample, all of the following criteria must be met:

• The patient had pathologically proven bladder cancer (any stage).
• All the data required are available from patient's records.

There are no restrictions regarding operative technique (cystectomy or cystoscopy).

• Many patients may no longer be alive, or no longer be in contact with the investigation sites. Thus, patients will not be required to give their informed consent before inclusion in the study.

Exclusion criteria

• Not applicable.

Trial design

156 participants in 1 patient group

Cancer Group

Treatment:

Other: Data acquisition and analysis